Noteworthy - Pharmaceutical Executive



Capturing the Real Value from a Pharma Spinout

July 9, 2014

The pharma spin market is moving up a gear as companies see the imperative to tap into brand value. Allen Gove explains how understanding what the company is about is critical to bolstering the value of the product.

Opioids: Don't Fix the Blame, Fix the Problem

July 3, 2014

Google "opioid abuse deterrence" and you'll find a lot of hits from lawyers and officials. What you won't find is a lot of expert thinking from FDA. That needs to change, says Peter J. Pitts of the Center for Medicine in the Public Health.

"Evidence" Trail Elusive

July 2, 2014

The potential of comparative effective research in transforming healthcare remains untapped, but the opportunities are there, writes Michael Christel.

Surviving the Emerging Market Price Wars: Three Myths & Three Lessons

June 29, 2014

How big Pharma stalwarts can avoid a corrosive battle of attrition with local competitors and instead obtain the long-term goal of a stable pricing environment.

Adaptive Trial Design: Prepping for Adoption

June 19, 2014

As interest grows in this productivity-enhancing tool for seamless drug development, there is a need for a better working consensus on standardized metrics that monitor progress and certify success.

Promoting Adherence: From Force to Finesse

June 16, 2014

Non-adherence, in the US alone, is a $100-billion-a-year problem. Healthcare players are touting patient education and engagement as the keys to better adherence rates. Ben Comer reports.

What Price Innovation?

June 16, 2014

Payers are seeking clear assessment of drug value to rationalize high drug prices. This issue has moved to center stage due to mounting concern over the high price for Gilead's Sovaldi, writes Jill Wechsler.

Pharma 50 Trends: Past, Present, and Future

June 9, 2014

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.

Immunotherapies: The New Hope for Cancer Treatment

June 9, 2014

The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey


Click here